Reports
Sale
Panic Disorder Market Size, Share, Trends, Analysis, Outlook: By Type: Agoraphobia, Social Anxiety Disorder (SAD), Obsessive-Compulsive Disorder (OCD), Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Others: By Therapy; By Drug Class; By Route of Administration; Regional Analysis; Patent Analysis; Supplier Landscape; 2024-2032
Panic Disorder Market Outlook
The panic disorder market size in the 7 major markets was valued at USD 9.7 billion in 2023, driven by the increased emphasis on improving mental health. The market is expected to grow at a CAGR of 4.18% during the forecast period of 2024-2032, with the values likely to rise from USD 10.1 billion in 2024 to USD 14 billion by 2032.
Panic Disorder: Introduction
Panic disorder is characterized by a condition with recurring and frequent panic attacks. They are repeated episodes of intense anxiety and fear, accompanied by physical symptoms like nausea, trembling, sweating and palpitations. Symptoms can also be triggered using amphetamines, cocaine, marijuana, hallucinogens, alcohol, and other drugs. Panic disorders are frequently treated through antidepressants, benzodiazepines, cognitive as well as behavioral therapies.
Panic Disorder Market Analysis
Pharmacological intervention is one of the most common panic disorder treatments. Over the years, there has been development of several medications like diazepam, alprazolam, clonazepam, paroxetine, venlafaxine, clomipramine, fluoxetine and adinazolam, helping many patients cope with the symptoms. Owing to the high panic disorder market demand, the FDA has also approved several medications such as Cymbalta (duloxetine delayed-release capsules), Effexor XR (venlafaxin HCL) and Zoloft (sertraline HCl) among others.
Along with pharmaceuticals, CBT (cognitive behavioral therapy) has shown promising results for treating panic disorders. Panic-focused psychodynamic psychotherapy, eye movement desensitization and reprocessing (EMDR) therapy and applied relaxation training (ART) are frequently applied, depending on the symptoms of the patients. Meditation is also promoted as a treatment for relieving anxiety symptoms.
The increasing integration of digital and artificial intelligence enabled tools into the medical ecosystem has propelled the panic disorder market growth. Smartphone apps to help manage anxiety have emerged in the market. For instance, the Mindable app, developed by professors at Constructor University in Bremen has been approved to manage panic disorder and agoraphobia. Similarly, Apple has launched their ‘Rootd’, facilitating the consumers with panic conditions.
Panic Disorder Market Segmentation
Market Breakup by Type
- Agoraphobia
- Social Anxiety Disorder (SAD)
- Obsessive-Compulsive Disorder (OCD)
- Bipolar Disorder
- Post-Traumatic Stress Disorder (PTSD)
- Specific Phobias, Generalized Anxiety Disorder (GAD)
- Major Depressive Disorder (MDD)
- Others
Market Breakup by Therapy
- Electroconvulsive Therapy ECT
- Cognitive-Behavioral Therapy (CBT)
Market Breakup by Drug Class
- Benzodiazepines (BZD)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Monoamine Oxidase Inhibitors (MAOIs)
- Anti-Depressants
- Tricyclic Antidepressants (TCAs)
- Pregabalin
- Buspirone
- Sertraline
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Panic Disorder Market Overview
The United States hold a significant panic disorder market share and is likely to continue dominating the market in the coming years as well. With prominent companies prevailing in the region, the frequency of drug development and approvals is high. There is rising awareness on mental health related issues with government and private foundations stepping in with campaigns and seminars to impart relevant knowledge on the issues.
In Europe, traditional techniques like aromatherapy and meditation are on the rise. The EU commission has announced a hefty investment of 6 million euros as a part of their mental health strategy. Moreover, workplace mental health initiatives have also been taken on the psychosocial risks of burnout in offices.
The Asia Pacific panic disorder market value is anticipated to grow with reducing stigmatization of mental health issues. With the help non-profit organizations and government campaigns, the masses are getting more aware about the condition. Moreover, the region is also experiencing improvements in the healthcare ecosystem to provide better treatment alternatives to the patients.
Panic Disorder Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd.
- Mylan
- AstraZeneca
- Abbott
- Baxter
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Recordati S.p.A.
- Boehringer Ingelheim International GmbH.
- Neurocrine Biosciences, Inc
- Recordati S.p.A.
- Sanofi
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Therapy |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Panic Disorder Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Panic Disorder Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Panic Disorder Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Panic Disorder Epidemiology Forecast (2017-2032)
5.3.1 Germany Panic Disorder Epidemiology Forecast (2017-2032)
5.3.2 France Panic Disorder Epidemiology Forecast (2017-2032)
5.3.3 Italy Panic Disorder Epidemiology Forecast (2017-2032)
5.3.4 Spain Panic Disorder Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Panic Disorder Epidemiology Forecast (2017-2032)
5.4 Japan Panic Disorder Epidemiology Forecast (2017-2032)
6 Panic Disorder Market Overview – 7MM
6.1 Panic Disorder Market Historical Value (2017-2023)
6.2 Panic Disorder Market Forecast Value (2024-2032)
7 Panic Disorder Market Landscape – 7MM
7.1 Panic Disorder Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Panic Disorder Product Landscape
7.2.1 Analysis by Diseases Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
8 Panic Disorder Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Panic Disorder Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Panic Disorder Market Segmentation – 7MM
11.1 Panic Disorder Market by Type
11.1.1 Market Overview
11.1.2 Agoraphobia
11.1.3 Social Anxiety Disorder (SAD)
11.1.4 Obsessive-Compulsive Disorder (OCD)
11.1.5 Bipolar Disorder
11.1.6 Post-Traumatic Stress Disorder (PTSD)
11.1.7 Specific Phobias, Generalized Anxiety Disorder (GAD)
11.1.8 Major Depressive Disorder (MDD)
11.1.9 Others
11.2 Panic Disorder Market by Therapy
11.2.1 Market Overview
11.2.2 Electroconvulsive Therapy ECT
11.2.3 Cognitive-Behavioral Therapy (CBT)
11.3 Panic Disorder Market by Drug Class
11.3.1 Market Overview
11.3.2 Benzodiazepines (BZD)
11.3.3 Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
11.3.4 Monoamine Oxidase Inhibitors (MAOIs)
11.3.5 Anti-Depressants
11.3.6 Tricyclic Antidepressants (TCAs)
11.3.7 Pregabalin
11.3.8 Buspirone
11.3.9 Sertraline
11.3.10 Others
11.4 Panic Disorder Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.5 Panic Disorder Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Panic Disorder Market
12.1 Panic Disorder Market Historical Value (2017-2023)
12.2 Panic Disorder Market Forecast Value (2024-2032)
12.3 Panic Disorder Market by Disease Type
12.4 Panic Disorder Market by Treatment Type
13 EU-4 and United Kingdom Panic Disorder Market
13.1 Panic Disorder Market Historical Value (2017-2023)
13.2 Panic Disorder Market Forecast Value (2024-2032)
13.3 Germany Panic Disorder Market Overview
13.3.1 Panic Disorder Market by Disease Type
13.3.2 Panic Disorder Market by Treatment Type
13.4 France Panic Disorder Market Overview
13.4.1 Panic Disorder Market by Disease Type
13.4.2 Panic Disorder Market by Treatment Type
13.5 Italy Panic Disorder Market Overview
13.5.1 Panic Disorder Market by Disease Type
13.5.2 Panic Disorder Market by Treatment Type
13.6 Spain Panic Disorder Market Overview
13.6.1 Panic Disorder Market by Disease Type
13.6.2 Panic Disorder Market by Treatment Type
13.7 United Kingdom Panic Disorder Market Overview
13.7.1 Panic Disorder Market by Disease Type
13.8 Panic Disorder Market by Treatment Type
14 Japan Panic Disorder Market
14.1 Panic Disorder Market Historical Value (2017-2023)
14.2 Panic Disorder Market Forecast Value (2024-2032)
14.3 Panic Disorder Market by Disease Type
14.4 Panic Disorder Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Teva Pharmaceutical Industries Ltd
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Sun Pharmaceutical Industries Ltd.
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Mylan
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 AstraZeneca
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Abbott
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.5.6 BaxterFinancial Analysis
20.5.7 Product Portfolio
20.5.8 Demographic Reach and Achievements
20.5.9 Mergers and Acquisition
20.5.10 Certifications
20.6 Baxter
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Bristol-Myers Squibb Company
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Eli Lilly and Company
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 F. Hoffmann-La Roche Ltd
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 GlaxoSmithKline plc
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Recordati S.p.A.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Boehringer Ingelheim International GmbH.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Neurocrine Biosciences, Inc
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Recordati S.p.A.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Sanofi
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Panic Disorders Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 9.7 billion in 2023, driven by the increasing awareness on improving mental health.
The market is anticipated to grow at a CAGR of 4.18% during the forecast period of 2024-2032, likely to reach a market value of USD 14 billion by 2032.
The market demand is driven by the increasing prevalence of high stress inducing lifestyle in people around the major markets.
Increasing application of smart phone mobile apps to treat panic and anxiety symptoms is the current market trends. Apps like Mindable and Rootd have surfaced in the market.
Based on types, the market is divided into agoraphobia, social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), bipolar disorder, post-traumatic stress disorder (PTSD), specific phobias, generalized anxiety disorder (GAD), and major depressive disorder (MDD), among others.
It includes electroconvulsive therapy (ECT) and cognitive-behavioral therapy (CBT).
Benzodiazepines (BZD), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), monoamine oxidase inhibitors (MAOIs), anti-depressants, tricyclic antidepressants (TCAs), pregabalin, buspirone, sertraline, among others are common drug class in the market.
The route of administration can be oral and parenteral, among others.
The 7 major markets include the United States, Japan, EU-4 and the United Kingdom. EU-4 is divided into Germany, France, Italy, and Spain.
Key players involved in the market are Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mylan, AstraZeneca, Abbott, Baxter, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Recordati S.p.A., Boehringer Ingelheim International GmbH., Neurocrine Biosciences, Inc, and Sanofi.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER